Abstract:Background Small interfering RNA (siRNA) holds great promise for treating various lung diseases, but the lack of safe and efficient pulmonary siRNA delivery systems has hindered its advance into the clinics. The epidermal growth factor receptor (EGFR) which promotes cell proliferation, and the programmed cell death ligand 1 (PD-L1) which plays a crucial role in suppressing cytotoxic T cells activity, are two important targets for treating non-small cell lung cancer (NSCLC). Here, we explored the potential of PEG 12 -KL4, a synthetic peptide, to deliver siRNA to various NSCLC cells and to lung tissues in mice. Methods PEG 12 -KL4 was used to transfect siRNAs targeted at both EGFR and PD-L1 into NSCLC cells. Immunoblotting was used to evaluate the siRNA silencing effects in HCC827 and NCI-H1975 NSCLC cells. CD8+ T cell-mediated NSCLC cell killing was employed to demonstrate the functional effects of PD-L1 siRNA knock-down. Fluorescent siRNAs were used to visualise siRNA uptake in cells as well as to enable biodistribution studies in BALB/c mice. Results Our results showed that PEG 12 -KL4 was efficient in mediating siRNA knock-down of EGFR and PD-L1 in various NSCLC cells. Importantly, the PEG 12 -KL4 peptide enabled significantly better siRNA delivery than the commercial Lipofectamine 2000 reagent. We hypothesised that PEG 12 -KL4 peptide enabled siRNA to either escape from or bypass endosomal degradation as indicated by confocal fluorescence imaging. Notably, combined knock-down of EGFR and PD-L1 in NCI-H1975 cells resulted in better effector T cell-mediated cancer cell killing than knock-down of PD-L1 alone. Moreover, biodistribution of PEG 12 -KL4/siRNA complexes following intravenous administration revealed poor lung delivery with the fluorescent siRNA accumulating in the liver. In contrast, intratracheal delivery of PEG 12 -KL4/siRNA complexes resulted in the fluorescent siRNA to be detected in the lung with retarded renal excretion. Conclusion In conclusion, we demonstrated that the co-delivery of siRNAs targeting EGFR and PD-L1 using PEG 12 -KL4 is feasible and represents a promising future strategy to treat NSCLC, whereby pulmonary siRNA delivery is favourable to intravenous administration.

Pulmonary Delivery of Polyplexes for Combined PAI-1 Gene Silencing and CXCR4 Inhibition to Treat Lung Fibrosis.

Treatment of acute lung injury and early- and late-stage pulmonary fibrosis with combination emulsion siRNA polyplexes

Co-delivery of siPTPN13 and siNOX4 via (myo)fibroblast-targeting polymeric micelles for idiopathic pulmonary fibrosis therapy

Pulmonary fibroblast-specific delivery of siRNA exploiting exosomes-based nanoscaffolds for IPF treatment

Targeted Dual Small Interfering Ribonucleic Acid Delivery Via Non-Viral Polymeric Vectors for Pulmonary Fibrosis Therapy

Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis

Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge

Double Braking Effects of Nanomedicine on Mitochondrial Permeability Transition Pore for Treating Idiopathic Pulmonary Fibrosis

A pH sensitive co-delivery system of siRNA and doxorubicin for pulmonary administration to B16F10 metastatic lung cancer

Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG 12 -KL4 peptide to the lungs as potential strategy against non-small cell lung cancer

Evaluation of the Antifibrotic Potency by Knocking Down SPARC, CCR2 and SMAD3

Local Administration of Liposomal-Based Plekhf1 Gene Therapy Attenuates Pulmonary Fibrosis by Modulating Macrophage Polarization

Macrophage‐targeted delivery of siRNA to silence Mecp2 gene expression attenuates pulmonary fibrosis

Pulmonary delivery of therapeutic proteins based on zwitterionic chitosan-based nanocarriers for treatment on bleomycin-induced pulmonary fibrosis

A Fibroblastic Foci-Targeting and Hypoxia-Cleavable Delivery System of Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis.

A Novel Fluorinated Polyethyleneimine with Microrna-942-5p-sponges Polyplex Gene Delivery System for Non-Small-cell Lung Cancer Therapy.

Pathological Collagen Targeting and Penetrating Liposomes for Idiopathic Pulmonary Fibrosis Therapy

Efficient Transfected Liposomes Co-Loaded with Pnrf2 and Pirfenidone Improves Safe Delivery for Enhanced Pulmonary Fibrosis Reversion

EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.

Cyclam-Modified PEI for Combined VEGF siRNA Silencing and CXCR4 Inhibition To Treat Metastatic Breast Cancer

Nanoengineered immunosuppressive therapeutics modulating M1/M2 macrophages into the balanced status for enhanced idiopathic pulmonary fibrosis therapy